checkAd

     105  0 Kommentare Ocular Therapeutix To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting

    Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced two scientific presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting being held May 16-19, 2022 in Washington, D.C. and virtually.

    “We have demonstrated the flexibility of our hydrogel platform across multiple ophthalmic indications and are excited to be presenting data using the hydrogel platform in gene therapy delivery at the ASGCT Annual Meeting,” commented Michael Goldstein, MD, MBA, President, Ophthalmology and Chief Medical Officer of Ocular Therapeutix. “The pre-clinical studies highlight data demonstrating our hydrogel platform’s potential to safely and durably deliver an adeno-associated virus (AAV) gene therapy in animal models.”

    Ocular Therapeutix Presentations at ASGCT:

    • Title: Reduced Ocular Inflammation and Improved GFP Expression in Rabbits with Controlled Release of Adeno-Associated Virus from Degradable Hydrogel Implants
      Session Title: Ophthalmic and Auditory Diseases
      Session Date/Times: Thursday May 19, 2022 11:00 AM – 11:15 AM ET
      Presentation type: Podium Presentation
      Presenter: Steven Lu, PhD and Meryem Pehlivaner, PhD
    • Title: Development of Hydrogel Implants for the Sustained Delivery of Adeno-Associated Viruses in Ocular Gene Therapy
      Session Title: Ophthalmic and Auditory Diseases
      Session Date/Times: Monday, May 16, 2022 5:50 PM - 6:30 PM ET
      Presentation type: Poster (Board No. M-167)
      Presenter: Steven Lu, PhD

    About Ocular Therapeutix, Inc.

    Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Ocular Therapeutix’s earlier stage development assets includes OTX-TKI (axitinib intravitreal implant), currently in Phase 1 clinical trials for the treatment of wet AMD and other retinal diseases. OTX-TIC (travoprost intracameral implant) is in a Phase 2 clinical trial to evaluate the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Ocular Therapeutix has also completed Phase 2 clinical trials for OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix's first product, ReSure Sealant, is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.

    Seite 1 von 3


    Business Wire (engl.)
    0 Follower
    Autor folgen

    Ocular Therapeutix To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced two scientific presentations at the American …